Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.550
+0.040 (2.65%)
At close: Feb 11, 2026, 4:00 PM EST
1.560
+0.010 (0.65%)
Pre-market: Feb 12, 2026, 4:35 AM EST
Akebia Therapeutics Employees
Akebia Therapeutics had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$1,243,486
Profits / Employee
-$87,873
Market Cap
411.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 181 | 14 | 8.38% | 181 | 0 |
| Dec 31, 2023 | 167 | -38 | -18.54% | 167 | 0 |
| Dec 31, 2022 | 205 | -221 | -51.88% | 204 | 1 |
| Dec 31, 2021 | 426 | 46 | 12.11% | 426 | 0 |
| Dec 31, 2020 | 380 | 20 | 5.56% | 379 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 869 |
| Kamada | 420 |
| Lifecore Biomedical | 406 |
| Evolus | 329 |
| Aquestive Therapeutics | 142 |
| SIGA Technologies | 46 |
AKBA News
- 7 days ago - Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 9 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts - Seeking Alpha
- 4 weeks ago - Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewsWire
- 2 months ago - Akebia Announces Establishment of Rare Kidney Disease Pipeline - GlobeNewsWire
- 2 months ago - Q32 Bio Sells Complement Inhibitor ADX-097 - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire